
We Develop Pan Coronavirus Antivirals
HALO'S PROPRIETARY FREE FATTY ACID FORMULA IS A PAN CORONAVIRUS ANTIVIRAL
The pocket and antiviral mechanism we discovered are fully conserved in:
- SARS1 (2003), MERS (2012) and SARS-CoV-2 (2019)
- all Variants of Concern (VOC) alpha, beta, delta, omicron

OUR PIPELINE & SCIENCE
INVESTMENT, LICENSING, AND PARTNERING
Please contact us for partnering, licensing, or investment opportunities in pan coronavirus antivirals and potential antiviral drugs for Covid-19.
Our Company
Halo Executive Team

Prof. Adam Finn
- Head clinician in UK wide RECOVERY trial ongoing for COVID-19
- Designing our Clinical Trials
- Expert in viral transmission New York Times Article by Adam
NEWS

A new Covid sub-variant is causing some concern in the US, where it is spreading rapidly.
Some cases have also been recorded in the UK, so what do you need to know about XBB.1.5?

About 40% of confirmed U.S. Covid cases are caused by the XBB.1.5 strain, up from 20% a week ago.

What was it like to keep research work going during the worst of the pandemic? And how close are we to a vaccine that works against all current and future coronavirus variants?

Investigators at the University of Bristol and Biognos AB have identified a structural feature that distinguished the deadly coronavirus strains from harmless, common cold-causing variants. The findings, which were published in the Nov. 23, 2022
KEY PUBLICATIONS
Oskar Staufer, Kapil Gupta, Jochen Estebano Hernandez Bücher, Fabian Kohler, Christian Sigl, Gunjita Singh, Kate Vasileiou, Ana Yagüe Relimpio, Meline Macher, Sebastian Fabritz, Hendrik Dietz, Elisabetta Ada Cavalcanti Adam, Christiane Schaffitzel, Alessia Ruggieri, Ilia Platzman, Imre Berger & Joachim P. Spatz
Imre Berger, Christiane Schaffitzel
Contact Us
Halo Therapeutics
- Unit Dx, 1st Floor Room 101, St. Philips Central Albert Road, St. Philips, Bristol, England, BS2 0XJ
- +44 117 403 4035
- contact@halo-therapeutics.com